IKBKB and breast cancer: Whilst it is important to note that these findings do not exclude NFκB contribution to primary tumour growth, RANKL-induced osteoclast formation and osteoblast inhibition that have previously reported [48–51], our present data provide a plausible mechanism for the anti-migratory, anti-resorptive and osteoanabolic effects associated with IKKβ inhibition in the sub-clones of the osteotropic MDA-231 breast cancer cells used in this study.